Safe and Efficient Drug for Hunter Syndrome

  • Author: Anar Murphy
  • Published: 11 September 2014
  • Copyright: Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
  • Source / Publisher: Biotechnology & Bioengineering/John Wiley & Sons
thumbnail image: Safe and Efficient Drug for Hunter Syndrome

Mucopolysaccharidosis II (MPS II) or Hunter syndrome is an X-linked inherited lysosomal storage disease. This serious genetic disorder interferes with the body's ability to break down and recycle specific mucopolysaccharides. It is caused by a defective or missing enzyme, iduronate-2-sulfatase (IDS). IDS is a large molecule unable to pass the brain-blood barrier (BBB), making enzyme replacement therapies impossible.

To solve this issue, William Pardridge, ArmaGen Technologies, Inc., Calabasas, CA, USA, and colleagues reengineered IDS by fusing it with a monoclonal antibody against the human insulin receptor (HIRMAb). HIRMAb has an innate ability to cross the BBB via receptor-mediated transport on the endogenous BBB insulin receptor, making it a perfect molecular Trojan horse to shuttle IDS from blood into brain.
The researchers conducted the first safety pharmacology and pharmacokinetics study of the HIRMAb-IDS fusion protein in juvenile male Rhesus monkeys by infusing them with it intravenously on a weekly basis for 26 days at 3–30 mg/kg doses.

Continuous monitoring of the plasma clearance, pharmacokinetic profile and immunogenicity of the HIRMaB-IDS in the tested animals demonstrated that the new drug is safe and efficient for use in primates. This makes it suitable for future clinical trials.


 

Article Views: 2903

Sign in Area

Please sign in below

Additional Sign In options

Please note that to comment on an article you must be registered and logged in.
Registration is for free, you may already be registered to receive, e.g., the newsletter. When you register on this website, please ensure you view our terms and conditions. All comments are subject to moderation.

Article Comments - To add a comment please sign in

If you would like to reuse any content, in print or online, from ChemistryViews.org, please contact us first for permission and consult our permission guidance prior to making your request

Follow on Facebook Follow on Twitter Follow on YouTube Follow on LinkedIn Follow on Instagram RSS Sign up for newsletters

Magazine of Chemistry Europe (16 European Chemical Societies) published by Wiley-VCH